Belgian Cancer Registry

CANCER FACT SHEET 2024
BREAST CANCER
ICD-10 C50

CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative chance in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later (=200*1.05) and 255/100,000 over 5 years (=200*$(1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2024, obtained from the Statbel.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. For breast cancer, stage IV means the cancer has spread to other organs. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

- **Clinical stage:** Stage based on clinical examinations (e.g.: medical imaging, biopsies) to estimate the extent of the tumour. Clinical stage is established before the start of any treatment.
- **Pathological stage:** Stage based on pathological examinations of the tumour after surgery. **Pathological stage without neo-adjuvant therapy** is the pathological stage in the population that did not receive neo-adjuvant therapy prior to surgery. **Pathological stage after neo-adjuvant therapy** is the pathological stage in the population that did receive neo-adjuvant therapy prior to surgery.

- **Neo-adjuvant therapy (NAT):** Treatment (e.g.: chemotherapy) given prior to surgery, with the goal to shrink the tumour before operating.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

Belgian Cancer Registry

TABLE OF CONTENTS

1. CANCER INCIDENCE (FEMALES) 5

1.1. Female breast cancer incidence: by region 5

1.1.1. Female breast cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024 5

1.2. Female breast cancer incidence: by tumour stage 6

1.2.1. Female breast cancer incidence by clinical stage (cStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 6

1.2.2. Female breast cancer incidence by pathological stage among patients who have undergone surgery without neo-adjuvant therapy (pStage), by age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 7

1.2.3. Female breast cancer incidence by pathological stage among patients who have undergone surgery with neo-adjuvant therapy (ypStage), by age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 7

1.2.4. Female breast cancer incidence by stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 8

2. CANCER INCIDENCE TRENDS (FEMALES) 9

2.1. Female breast cancer incidence trends: by region 9

2.1.1. Female breast cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 9

2.2. Female breast cancer incidence trends: by tumour stage 10

2.2.1. Female breast cancer incidence trends by stage: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards 10

2.3. Female breast cancer incidence trends: by age group 11

2.3.1. Female breast cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 11

3. CANCER PREVALENCE (FEMALES) 12

3.1. Female breast cancer prevalence: by region 12

3.1.1. Female breast cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024 12

4. CANCER SURVIVAL (FEMALES) 13

4.1. Female breast cancer survival: by region 13

4.1.1. Female breast cancer survival by region and age group: number at risk and net survival probabilities, 2015-2024 13

4.2. Female breast cancer survival: by tumour stage 15

4.2.1. Female breast cancer survival by clinical stage (cStage): number at risk and net survival probabilities, 2015-2024 15

4.2.2. Female breast cancer survival by pathological stage among patients who have undergone surgery without neo-adjuvant therapy (pStage): number at risk and net survival probabilities, 2015-2024 16

4.2.3. Female breast cancer survival by pathological stage among patients who have undergone surgery with neo-adjuvant therapy (ypStage): number at risk and net survival probabilities, 2015-2024 16

4.2.4. Female breast cancer survival by stage: number at risk and net survival probabilities, 2015-2024 17

5. CANCER SURVIVAL TRENDS (FEMALES) 18

5.1. Female breast cancer survival trends: by tumour stage 18
5.1.1. Female breast cancer survival trends by stage: number at risk and net survival probabilities, 2004-2024 18
6. CANCER MORTALITY (FEMALES) 20
6.1. Female breast cancer mortality: by region 20
6.1.1. Female breast cancer mortality* by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023 20
7. CANCER MORTALITY TRENDS (FEMALES) 21
7.1. Female breast cancer mortality trends: by region 21
7.1.1. Female breast cancer mortality* trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 21
7.2. Female breast cancer mortality trends: by age group 23
7.2.1. Female breast cancer mortality* trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 23
8. CANCER INCIDENCE (MALES) 24
8.1. Male breast cancer incidence: by region 24
8.1.1. Male breast cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024 24
9. CANCER INCIDENCE TRENDS (MALES) 25
9.1. Male breast cancer incidence trends: by region 25
9.1.1. Male breast cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 25
10. CANCER PREVALENCE (MALES) 26
10.1. Male breast cancer prevalence: by region 26
10.1.1. Male breast cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024 26
11. CANCER SURVIVAL (MALES) 27
11.1. Male breast cancer survival: by region 27
11.1.1. Male breast cancer survival by region and age group: number at risk and net survival probabilities, 2015-2024 27
12. CANCER SURVIVAL TRENDS (MALES) 29
12.1. Male breast cancer survival trends 29
12.1.1. Male breast cancer survival trends: number at risk and net survival probabilities, 2004-2024 29
13. CANCER MORTALITY (MALES) 30
13.1. Male breast cancer mortality 30
13.1.1. Male breast cancer mortality*: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023 30
14. CANCER MORTALITY TRENDS (MALES) 31
14.1. Male breast cancer mortality trends 31
14.1.1. Male breast cancer mortality* trends: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 31

Belgian Cancer Registry

1. CANCER INCIDENCE (FEMALES)

1.1. Female breast cancer incidence: by region

1.1.1. Female breast cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Females																						
Belgium	0	0	0	0	5	57	180	360	647	946	1,108	1,157	1,425	1,482	1,291	1,322	851	593	266	51	11,741	189.8
	[0.0]	[0.0]	[0.0]	[0.0]	[1.5]	[15.8]	[46.0]	[93.7]	[167.5]	[255.8]	[287.4]	[294.6]	[369.2]	[429.7]	[432.5]	[516.4]	[489.4]	[437.5]	[369.2]	[236.0]	[196.8]	(186.3; 193.2)
Brussels	0	0	0	0	1	7	23	38	63	99	107	75	103	100	86	97	55	24	17	5	900	169.3
	[0.0]	[0.0]	[0.0]	[0.0]	[2.3]	[12.3]	[42.1]	[78.0]	[138.5]	[236.5]	[277.6]	[218.0]	[337.1]	[397.6]	[399.4]	[523.2]	[429.5]	[248.7]	[301.3]	[238.2]	[141.2]	(158.1; 180.5)
Flanders	0	0	0	0	2	31	94	191	379	552	676	712	837	866	762	799	544	375	163	27	7,010	190.6
	[0.0]	[0.0]	[0.0]	[0.0]	[1.1]	[15.6]	[43.0]	[88.8]	[170.4]	[261.7]	[305.2]	[305.4]	[361.2]	[419.1]	[430.2]	[516.4]	[496.3]	[432.3]	[359.9]	[209.6]	[203.5]	(186.0; 195.1)
Wallonia	0	0	0	0	2	19	63	131	205	295	325	370	485	516	443	426	252	194	86	19	3,831	194.3
	[0.0]	[0.0]	[0.0]	[0.0]	[1.8]	[17.8]	[53.2]	[109.0]	[173.3]	[252.2]	[259.0]	[295.7]	[392.1]	[456.1]	[443.6]	[514.7]	[489.5]	[495.6]	[407.5]	[286.4]	[203.3]	(188.1; 200.5)

1.2. Female breast cancer incidence: by tumour stage

1.2.1. Female breast cancer incidence by clinical stage (cStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

cStage	N[CR]				ESR2013 (95%CI)
	15-49	50-69	70+	All ages 0+	
I	799 [31.2]	2,777 [184.0]	1,817 [189.7]	5,393 [90.4]	88.0 (85.6; 90.4)
II	937 [36.6]	1,605 [106.4]	1,620 [169.2]	4,162 [69.8]	67.1 (65.0; 69.1)
III	251 [9.8]	297 [19.7]	368 [38.4]	916 [15.4]	14.6 (13.6; 15.5)
IV	133 [5.2]	305 [20.2]	439 [45.8]	877 [14.7]	13.9 (13.0; 14.8)
X/NA	75 [2.9]	188 [12.5]	130 [13.6]	393 [6.6]	6.3 (5.7; 6.9)

1.2.2. Female breast cancer incidence by pathological stage among patients who have undergone surgery without neo-adjuvant therapy (pStage), by age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

pStage	N[CR]				ESR2013 (95%CI)
	15-49	50-69	70+	All ages 0+	
I	702 [27.4]	2,511 [166.4]	1,431 [149.4]	4,644 [77.8]	76.5 (74.3; 78.7)
II	424 [16.5]	1,171 [77.6]	1,186 [123.8]	2,781 [46.6]	44.7 (43.0; 46.4)
III	81 [3.2]	230 [15.2]	231 [24.1]	542 [9.1]	8.6 (7.9; 9.4)
IV	15 [0.6]	43 [2.8]	35 [3.7]	93 [1.6]	1.5 (1.2; 1.8)
X/NA	158 [6.2]	362 [24.0]	1,176 [122.8]	1,696 [28.4]	24.6 (23.4; 25.7)

1.2.3. Female breast cancer incidence by pathological stage among patients who have undergone surgery with neo-adjuvant therapy (ypStage), by age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

ypStage	N[CR]				ESR2013 (95%CI)
	15-49	50-69	70+	All ages 0+	
I	171 [6.7]	212 [14.0]	84 [8.8]	467 [7.8]	7.9 (7.2; 8.6)
II	162 [6.3]	169 [11.2]	81 [8.5]	412 [6.9]	7.0 (6.3; 7.7)
III	72 [2.8]	84 [5.6]	43 [4.5]	199 [3.3]	3.3 (2.9; 3.8)
IV	3 [0.1]	7 [0.5]	0 [0.0]	10 [0.2]	0.2 (0.1; 0.3)
X/NA	407 [15.9]	383 [25.4]	107 [11.2]	897 [15.0]	15.4 (14.4; 16.4)

1.2.4. Female breast cancer incidence by stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Stage	N[CR]				ESR2013 (95%CI)
	15-49	50-69	70+	All ages 0+	
I	783 [30.6]	2,658 [176.1]	1,698 [177.3]	5,139 [86.1]	84.0 (81.6; 86.3)
II	955 [37.3]	1,713 [113.5]	1,693 [176.8]	4,361 [73.1]	70.3 (68.2; 72.4)
III	307 [12.0]	462 [30.6]	477 [49.8]	1,246 [20.9]	20.0 (18.8; 21.1)
IV	133 [5.2]	307 [20.3]	440 [45.9]	880 [14.7]	13.9 (13.0; 14.9)
X/NA	17 [0.7]	32 [2.1]	66 [6.9]	115 [1.9]	1.7 (1.4; 2.0)

Belgian Cancer Registry

2. CANCER INCIDENCE TRENDS (FEMALES)

2.1. Female breast cancer incidence trends: by region

2.1.1. Female breast cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	**N**	9,375	9,378	9,489	9,687	9,582	9,598	9,899	10,544	10,550	10,707	10,480	10,405	10,784	10,655	10,926	10,997	10,495	11,326	11,160	11,548	11,741		
	CR	176.6	175.8	176.8	179.3	176.1	175.0	179.1	188.9	187.7	189.4	184.6	182.4	188.2	185.2	189.1	189.5	179.9	193.8	190.0	194.5	196.8		
	ESR2013	183.6	180.8	181.6	182.6	178.5	177.0	181.0	190.7	188.0	189.7	184.8	181.3	186.4	182.3	185.6	185.5	175.8	188.5	184.0	188.6	189.8	0.1 (0.0; 0.3)	2004-2024
Brussels	**N**	930	866	932	924	864	901	920	927	924	955	964	899	942	902	963	961	922	953	899	985	900		
	CR	179.0	165.5	176.1	172.9	159.4	163.1	163.5	160.7	157.7	161.1	161.5	149.2	154.9	148.1	157.3	156.0	148.6	153.5	144.5	155.6	141.2		
	ESR2013	205.8	186.8	202.1	199.7	185.8	191.7	191.9	193.6	188.8	195.6	196.0	182.3	186.8	178.3	190.5	187.8	178.4	183.2	171.9	186.6	169.3	-0.6 (-0.8; -0.3)	2004-2024
Flanders	**N**	5,270	5,462	5,489	5,670	5,486	5,541	5,717	6,115	6,087	6,196	6,031	6,137	6,308	6,287	6,347	6,489	6,301	6,861	6,676	6,804	7,010		
	CR	172.8	178.3	178.2	182.9	175.7	176.2	180.5	191.5	189.3	191.8	185.9	188.2	192.5	190.8	191.6	194.9	188.2	204.2	197.4	198.8	203.5		
	ESR2013	176.5	179.8	178.6	181.8	173.7	173.0	177.4	187.5	183.6	186.0	180.0	180.3	184.0	181.3	181.8	184.9	178.1	192.4	185.3	187.0	190.6	0.3 (0.1; 0.5)	2004-2024
Wallonia	**N**	3,175	3,050	3,068	3,093	3,232	3,156	3,262	3,502	3,539	3,556	3,485	3,369	3,534	3,466	3,616	3,547	3,272	3,512	3,585	3,759	3,831		
	CR	182.4	174.5	174.6	174.9	181.7	176.6	181.4	193.4	194.3	194.5	190.0	183.1	191.5	187.3	195.0	190.9	175.6	188.4	191.7	199.9	203.3		
	ESR2013	191.3	181.4	181.9	180.1	186.0	180.7	184.6	196.5	196.3	195.7	191.4	183.6	191.1	186.0	191.8	186.7	171.4	183.0	185.5	193.1	194.3	0.1 (-0.2; 0.3)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Female breast cancer incidence trends: by tumour stage

2.2.1. Female breast cancer incidence trends by stage: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

Stage		2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
I	N	4,304	4,983	4,762	5,015	5,139		
	CR	73.8	85.3	81.1	84.5	86.1		
	ESR2013	73.1	84.0	79.7	82.7	84.0	1.2 (0.9; 1.6)	2004-2024
							2.7 (1.6; 3.9)	2004-2017
							3.2 (0.5; 6.1)	2018-2011
							0.7 (-0.5; 1.8)	2012-2024
II	N	4,080	4,266	4,269	4,372	4,361		
	CR	70.0	73.0	72.7	73.7	73.1		
	ESR2013	68.2	70.8	70.2	71.2	70.3	0.6 (0.5; 0.7)	2004-2024
III	N	1,165	1,108	1,135	1,178	1,246		
	CR	20.0	19.0	19.3	19.8	20.9		
	ESR2013	19.3	18.1	18.3	19.1	20.0	-0.9 (-1.3; -0.4)	2004-2024
							0.8 (-0.2; 1.8)	2004-2013
							-4.0 (-5.9; -2.0)	2014-2017
							-1.1 (-2.4; 0.3)	2018-2024
IV	N	777	816	868	861	880		
	CR	13.3	14.0	14.8	14.5	14.7		
	ESR2013	12.7	13.2	13.9	13.7	13.9	2.4 (1.9; 2.9)	2004-2024
X/NA	N	169	153	126	122	115		
	CR	2.9	2.6	2.1	2.1	1.9		
	ESR2013	2.5	2.3	1.9	1.9	1.7	-12.6 (-13.3; -11.9)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Female breast cancer incidence trends: by age group

2.3.1. Female breast cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, %	(95%CI)	Period
15-49	**N**	2,122	2,190	2,175	2,256	2,158	2,094	2,125	2,203	2,082	2,175	2,088	2,027	2,023	2,035	1,967	2,050	2,025	2,076	2,021	2,185	2,195			
	CR	85.9	88.6	87.7	90.7	86.5	83.7	84.8	87.6	82.7	86.4	83.2	81.0	81.0	81.6	78.9	82.2	81.0	83.0	80.5	85.9	85.6			
	ESR2013	85.5	87.5	86.5	89.5	85.3	82.8	84.1	87.0	82.3	86.4	84.0	82.3	82.5	83.6	80.8	84.3	83.4	85.8	83.7	89.6	89.4	0.1	(-0.1; 0.3)	2004-2024
																							-0.4	(-0.7; -0.2)	2004-2018
																							1.4	(0.7; 2.0)	2019-2024
50-69	**N**	4,573	4,354	4,451	4,466	4,453	4,499	4,712	5,057	5,100	5,195	5,014	5,012	5,195	5,072	5,152	5,115	4,892	5,269	4,964	5,178	5,172			
	CR	388.3	365.0	367.5	363.0	356.2	354.3	364.4	382.7	376.6	376.0	357.1	351.3	359.3	348.6	352.4	348.2	331.1	354.6	332.0	343.9	342.7			
	ESR2013	390.1	366.4	369.9	365.2	358.3	356.2	366.6	385.3	379.0	377.9	358.3	352.2	359.9	349.1	352.6	348.2	330.5	353.6	330.5	342.3	340.2	-0.6	(-0.8; -0.3)	2004-2024
70+	**N**	2,680	2,834	2,863	2,965	2,971	3,005	3,062	3,284	3,368	3,337	3,378	3,366	3,566	3,548	3,807	3,832	3,578	3,981	4,175	4,185	4,374			
	CR	342.4	357.7	358.1	367.3	364.4	364.4	367.7	392.7	403.7	400.6	403.5	398.0	418.9	409.2	431.9	427.8	393.3	434.9	449.4	444.0	456.8			
	ESR2013	340.3	355.8	358.3	364.5	361.3	362.2	367.6	394.0	401.6	402.4	410.1	401.8	423.4	410.2	435.9	432.3	397.7	439.0	455.1	448.1	460.7	1.4	(1.2; 1.6)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

Belgian Cancer Registry

3. CANCER PREVALENCE (FEMALES)

3.1. Female breast cancer prevalence: by region

3.1.1. Female breast cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024

Region		Females				
		1-year	5-year	10-year	15-year	20-year
Belgium	**N**	11,439	51,010	91,153	123,595	147,666
	CR	190.8	850.8	1,520.3	2,061	2,463
	ESR2013	183.2	814.0	1,445.2	1,945.3	2,309.7
Brussels	**N**	876	4,169	7,523	10,276	12,315
	CR	136.8	650.9	1,174.6	1,604.5	1,922.9
	ESR2013	164.1	785.5	1,433.5	1,973.6	2,379.6
Flanders	**N**	6,853	30,721	54,613	73,667	87,878
	CR	197.8	886.6	1,576.2	2,126.1	2,536.2
	ESR2013	184.3	823.2	1,450.8	1,939.1	2,295.1
Wallonia	**N**	3,710	16,120	29,017	39,652	47,473
	CR	196.3	852.9	1,535.2	2,097.8	2,511.6
	ESR2013	186.6	807.7	1,443.2	1,957.6	2,329.2

Belgian Cancer Registry

4. CANCER SURVIVAL (FEMALES)

4.1. Female breast cancer survival: by region

4.1.1. Female breast cancer survival by region and age group: number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024			
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Females						
Belgium	**All ages 15+**	109,887	97.7% (97.6%; 97.8%)	94.6% (94.4%; 94.9%)	92.0% (91.7%; 92.4%)	87.8% (86.9%; 88.8%)
	15-49	20,565	99.3% (99.2%; 99.4%)	96.9% (96.6%; 97.2%)	94.6% (94.3%; 95.0%)	90.9% (90.2%; 91.5%)
	50-69	50,947	98.7% (98.6%; 98.8%)	96.5% (96.3%; 96.7%)	94.6% (94.3%; 94.9%)	91.2% (90.6%; 91.7%)
	70+	38,376	95.6% (95.3%; 95.9%)	91.0% (90.4%; 91.5%)	87.2% (86.4%; 88.1%)	81.6% (78.9%; 84.4%)
Brussels	**All ages 15+**	9,289	97.8% (97.4%; 98.3%)	94.8% (94.0%; 95.5%)	91.9% (90.8%; 93.0%)	90.5% (87.0%; 94.3%)
	15-49	2,185	99.4% (99.1%; 99.8%)	96.5% (95.6%; 97.3%)	93.6% (92.4%; 94.8%)	90.7% (88.8%; 92.8%)
	50-69	4,043	98.6% (98.2%; 99.0%)	96.2% (95.4%; 96.9%)	94.5% (93.5%; 95.5%)	90.8% (88.8%; 92.8%)
	70+	3,061	95.7% (94.6%; 96.8%)	91.8% (89.8%; 93.8%)	87.2% (84.3%; 90.3%)	89.7% (80.0%; 100.6%)
Flanders	**All ages 15+**	65,163	97.8% (97.7%; 98.0%)	94.8% (94.5%; 95.1%)	92.1% (91.7%; 92.5%)	86.7% (85.6%; 87.9%)
	15-49	11,896	99.3% (99.1%; 99.4%)	97.1% (96.8%; 97.5%)	95.0% (94.6%; 95.5%)	91.2% (90.3%; 92.0%)
	50-69	30,395	98.8% (98.7%; 99.0%)	96.8% (96.5%; 97.0%)	94.8% (94.5%; 95.1%)	91.4% (90.7%; 92.1%)
	70+	22,873	95.8% (95.4%; 96.2%)	90.9% (90.2%; 91.7%)	86.9% (85.8%; 88.0%)	77.9% (74.6%; 81.3%)
Wallonia	**All ages 15+**	35,435	97.5% (97.2%; 97.7%)	94.3% (93.9%; 94.7%)	92.0% (91.4%; 92.6%)	89.1% (87.4%; 90.9%)
	15-49	6,484	99.3% (99.1%; 99.6%)	96.6% (96.1%; 97.1%)	94.3% (93.6%; 95.0%)	90.4% (89.2%; 91.6%)

Net Survival Probability, 2015-2024						
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	50-69	16,509	98.4% (98.2%; 98.7%)	96.0% (95.6%; 96.4%)	94.2% (93.7%; 94.7%)	90.8% (89.8%; 91.9%)
	70+	12,442	95.2% (94.7%; 95.8%)	90.8% (89.8%; 91.8%)	87.9% (86.3%; 89.4%)	86.3% (81.1%; 91.7%)

4.2. Female breast cancer survival: by tumour stage

4.2.1. Female breast cancer survival by clinical stage (cStage): number at risk and net survival probabilities, 2015-2024

		Net Survival Probability, 2015-2024					
cStage	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	109,887	97.7% (97.6%; 97.8%)	96.2% (96.0%; 96.4%)	94.6% (94.4%; 94.9%)	93.1% (92.9%; 93.4%)	92.0% (91.7%; 92.4%)	87.8% (86.9%; 88.8%)
I	47,958	100.2% (100.1%; 100.3%)	100.5% (100.4%; 100.7%)	100.7% (100.5%; 101.0%)	100.9% (100.6%; 101.2%)	101.2% (100.8%; 101.5%)	102.5% (101.4%; 103.7%)
II	39,136	99.4% (99.2%; 99.6%)	98.3% (98.0%; 98.5%)	96.8% (96.4%; 97.2%)	95.0% (94.6%; 95.5%)	93.7% (93.1%; 94.3%)	87.7% (85.8%; 89.6%)
III	7,613	95.2% (94.6%; 95.8%)	89.9% (89.0%; 90.8%)	85.1% (84.0%; 86.3%)	81.0% (79.6%; 82.4%)	77.6% (76.0%; 79.3%)	62.2% (56.9%; 68.0%)
IV	7,725	78.8% (77.8%; 79.8%)	67.9% (66.8%; 69.1%)	58.0% (56.8%; 59.3%)	50.0% (48.7%; 51.4%)	43.4% (42.0%; 44.9%)	23.3% (20.7%; 26.3%)
X/NA	7,470	95.1% (94.5%; 95.8%)	93.2% (92.4%; 94.0%)	91.5% (90.6%; 92.5%)	89.9% (88.8%; 91.1%)	88.9% (87.6%; 90.3%)	84.3% (81.8%; 86.8%)

4.2.2. Female breast cancer survival by pathological stage among patients who have undergone surgery without neo-adjuvant therapy (pStage): number at risk and net survival probabilities, 2015-2024

		Net Survival Probability, 2015-2024					
pStage	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	92,563	97.3% (97.2%; 97.5%)	95.9% (95.7%; 96.1%)	94.4% (94.2%; 94.7%)	93.0% (92.7%; 93.3%)	91.9% (91.5%; 92.3%)	88.0% (86.9%; 89.0%)
I	42,672	100.8% (100.8%; 100.9%)	101.5% (101.4%; 101.6%)	102.0% (101.8%; 102.2%)	102.5% (102.3%; 102.8%)	103.1% (102.8%; 103.4%)	105.5% (104.4%; 106.5%)
II	27,706	100.7% (100.6%; 100.9%)	100.9% (100.6%; 101.1%)	100.6% (100.3%; 101.0%)	100.0% (99.6%; 100.5%)	99.6% (99.0%; 100.1%)	97.6% (95.6%; 99.6%)
III	6,497	98.4% (97.9%; 98.9%)	95.9% (95.1%; 96.7%)	93.4% (92.4%; 94.4%)	89.5% (88.2%; 90.8%)	85.9% (84.3%; 87.4%)	74.4% (70.6%; 78.4%)
IV	827	75.7% (72.7%; 78.8%)	65.8% (62.4%; 69.4%)	55.2% (51.5%; 59.2%)	48.1% (44.3%; 52.3%)	40.0% (36.1%; 44.4%)	27.7% (22.4%; 34.2%)
X/NA	14,876	81.5% (80.8%; 82.2%)	72.1% (71.2%; 73.0%)	63.5% (62.4%; 64.6%)	56.1% (54.9%; 57.4%)	50.8% (49.4%; 52.3%)	29.5% (26.5%; 33.0%)

4.2.3. Female breast cancer survival by pathological stage among patients who have undergone surgery with neo-adjuvant therapy (ypStage): number at risk and net survival probabilities, 2015-2024

		Net Survival Probability, 2015-2024					
ypStage	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	17,325	99.9% (99.8%; 100.1%)	97.8% (97.5%; 98.1%)	95.7% (95.3%; 96.2%)	94.0% (93.5%; 94.6%)	92.7% (92.1%; 93.3%)	86.6% (84.3%; 88.9%)
I	4,511	100.4% (100.3%; 100.6%)	99.6% (99.2%; 100.0%)	98.7% (98.1%; 99.3%)	97.9% (97.1%; 98.7%)	97.4% (96.5%; 98.4%)	94.2% (91.7%; 96.9%)
II	4,062	99.9% (99.6%; 100.3%)	96.8% (96.1%; 97.5%)	94.0% (93.1%; 95.0%)	91.4% (90.2%; 92.6%)	89.8% (88.4%; 91.2%)	83.6% (80.5%; 86.9%)
III	2,148	98.4% (97.7%; 99.1%)	91.3% (89.9%; 92.6%)	84.5% (82.7%; 86.3%)	80.2% (78.2%; 82.3%)	75.1% (72.8%; 77.5%)	58.7% (54.6%; 63.1%)
IV	152	93.5% (89.4%; 97.8%)	81.2% (74.9%; 88.0%)	72.3% (65.0%; 80.3%)	65.4% (57.5%; 74.5%)	59.9% (51.5%; 69.8%)	50.3% (37.5%; 67.5%)
X/NA	6,452	100.2% (100.1%; 100.3%)	99.8% (99.5%; 100.1%)	99.2% (98.7%; 99.6%)	98.5% (98.0%; 99.1%)	98.4% (97.8%; 99.1%)	94.6% (88.2%; 101.5%)

4.2.4. Female breast cancer survival by stage: number at risk and net survival probabilities, 2015-2024

Stage	N at risk	Net Survival Probability, 2015-2024 1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	109,887	97.7% (97.6%; 97.8%)	96.2% (96.0%; 96.4%)	94.6% (94.4%; 94.9%)	93.1% (92.9%; 93.4%)	92.0% (91.7%; 92.4%)	87.8% (86.9%; 88.8%)
I	46,887	100.2% (100.1%; 100.4%)	100.6% (100.4%; 100.7%)	100.8% (100.6%; 101.0%)	101.0% (100.7%; 101.3%)	101.4% (101.1%; 101.8%)	102.7% (101.6%; 103.9%)
II	41,296	99.5% (99.4%; 99.7%)	98.6% (98.4%; 98.9%)	97.5% (97.2%; 97.9%)	96.2% (95.7%; 96.6%)	95.3% (94.7%; 95.8%)	90.7% (88.9%; 92.5%)
III	11,944	96.7% (96.2%; 97.1%)	92.7% (92.1%; 93.4%)	89.1% (88.2%; 89.9%)	85.3% (84.3%; 86.3%)	81.8% (80.6%; 83.0%)	68.5% (65.2%; 71.9%)
IV	7,839	78.7% (77.8%; 79.7%)	67.9% (66.7%; 69.0%)	58.1% (56.8%; 59.3%)	50.1% (48.7%; 51.5%)	43.5% (42.1%; 45.0%)	24.1% (21.5%; 27.0%)
X/NA	1,938	81.3% (79.3%; 83.3%)	73.3% (70.8%; 75.8%)	66.7% (63.9%; 69.7%)	60.2% (56.9%; 63.7%)	56.1% (52.6%; 59.9%)	42.2% (36.6%; 48.7%)

Belgian Cancer Registry

5. CANCER SURVIVAL TRENDS (FEMALES)

5.1. Female breast cancer survival trends: by tumour stage

5.1.1. Female breast cancer survival trends by stage: number at risk and net survival probabilities, 2004-2024

Period	Stage	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2009	**Total**	56,963	97.0% (96.9%; 97.2%)	92.2% (91.9%; 92.6%)	88.1% (87.7%; 88.5%)
	I	21,076	100.4% (100.3%; 100.6%)	100.5% (100.2%; 100.8%)	100.4% (100.0%; 100.8%)
	II	20,266	99.5% (99.3%; 99.7%)	96.4% (95.9%; 96.9%)	93.3% (92.6%; 93.9%)
	III	7,180	96.2% (95.6%; 96.8%)	84.9% (83.8%; 86.0%)	74.3% (73.0%; 75.7%)
	IV	2,996	74.9% (73.3%; 76.5%)	48.6% (46.7%; 50.6%)	30.1% (28.3%; 32.0%)
	X/NA	5,458	88.1% (87.1%; 89.1%)	78.4% (77.0%; 79.8%)	71.1% (69.4%; 72.9%)
2010-2014	**Total**	52,110	97.4% (97.2%; 97.6%)	93.3% (93.0%; 93.6%)	89.9% (89.5%; 90.4%)
	I	21,730	100.4% (100.2%; 100.5%)	100.6% (100.3%; 100.9%)	100.7% (100.3%; 101.1%)
	II	18,398	99.5% (99.2%; 99.7%)	96.8% (96.3%; 97.3%)	94.1% (93.4%; 94.9%)
	III	6,655	96.5% (95.9%; 97.1%)	86.5% (85.4%; 87.6%)	78.4% (77.1%; 79.8%)
	IV	3,046	75.7% (74.1%; 77.3%)	51.7% (49.8%; 53.7%)	34.0% (32.1%; 36.0%)
	X/NA	2,284	83.5% (81.8%; 85.3%)	70.8% (68.4%; 73.3%)	60.9% (57.9%; 64.1%)
2015-2019	**Total**	53,676	97.6% (97.4%; 97.8%)	94.2% (93.8%; 94.5%)	91.5% (91.0%; 91.9%)
	I	22,691	100.4% (100.2%; 100.5%)	100.8% (100.5%; 101.1%)	101.4% (101.0%; 101.8%)
	II	19,953	99.4% (99.2%; 99.7%)	97.1% (96.6%; 97.6%)	94.8% (94.1%; 95.5%)
	III	6,117	96.4% (95.8%; 97.1%)	88.3% (87.2%; 89.5%)	81.2% (79.7%; 82.7%)

Period	Stage	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	IV	3,644	78.0% (76.5%; 79.4%)	55.7% (54.0%; 57.6%)	40.7% (38.9%; 42.6%)
	X/NA	1,277	81.6% (79.2%; 84.1%)	66.8% (63.4%; 70.4%)	56.0% (52.0%; 60.3%)
2020-2024	**Total**	56,218	97.8% (97.7%; 98.0%)	95.2% (94.8%; 95.5%)	92.8% (92.3%; 93.4%)
	I	24,196	100.1% (100.0%; 100.3%)	100.7% (100.4%; 101.1%)	101.6% (101.0%; 102.2%)
	II	21,343	99.7% (99.4%; 99.9%)	97.9% (97.4%; 98.4%)	96.0% (95.1%; 96.9%)
	III	5,827	96.9% (96.3%; 97.5%)	89.9% (88.7%; 91.2%)	82.3% (80.2%; 84.4%)
	IV	4,195	79.4% (78.1%; 80.7%)	60.3% (58.6%; 62.2%)	46.8% (44.4%; 49.3%)
	X/NA	661	80.4% (76.9%; 84.1%)	66.6% (61.5%; 72.1%)	57.7% (50.4%; 66.1%)

Belgian Cancer Registry

6. CANCER MORTALITY (FEMALES)

6.1. Female breast cancer mortality: by region

6.1.1. Female breast cancer mortality by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023*

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Belgium	0	0	0	0	0	1	6	16	48	59	91	121	163	195	213	297	263	303	243	90	2,109	31.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[1.5]	[4.2]	[12.5]	[16.1]	[23.4]	[30.5]	[42.7]	[57.6]	[71.7]	[120.9]	[151.0]	[226.4]	[342.9]	[432.3]	[35.5]	(29.6; 32.3)
Brussels	0	0	0	0	0	0	0	4	7	5	11	11	8	12	14	16	26	26	26	10	176	31.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[8.3]	[15.3]	[12.2]	[28.7]	[32.3]	[26.5]	[48.0]	[65.3]	[88.9]	[202.4]	[265.1]	[458.4]	[480.3]	[27.8]	(26.6; 36.1)
Flanders	0	0	0	0	0	1	2	8	29	34	44	71	104	107	122	176	163	188	144	49	1,242	30.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.9]	[3.8]	[13.1]	[16.3]	[19.6]	[30.0]	[45.5]	[52.9]	[69.5]	[117.1]	[148.9]	[220.3]	[327.3]	[399.9]	[36.3]	(28.3; 31.7)
Wallonia	0	0	0	0	0	0	4	4	12	20	36	39	51	76	77	105	74	89	73	31	691	32.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[3.3]	[3.4]	[10.2]	[16.9]	[28.7]	[30.8]	[41.5]	[68.2]	[77.0]	[135.6]	[142.5]	[230.1]	[344.4]	[478.1]	[36.7]	(30.1; 35.1)

Belgian Cancer Registry

7. CANCER MORTALITY TRENDS (FEMALES)

7.1. Female breast cancer mortality trends: by region

7.1.1. Female breast cancer mortality trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	2,276	2,254	2,248	2,348	2,347	2,348	2,352	2,388	2,312	2,288	2,237	2,167	2,226	2,195	2,222	2,075	2,058	2,048	2,107	2,109		
	CR	42.9	42.3	41.9	43.5	43.1	42.8	42.5	42.8	41.1	40.5	39.4	38.0	38.8	38.1	38.5	35.8	35.3	35.0	35.9	35.5		
	ESR2013	43.8	43.0	42.1	43.2	42.5	42.1	41.4	41.5	39.2	38.8	37.2	35.2	35.9	34.8	34.9	31.8	31.5	30.9	31.5	31.0	-1.9 (-2.1; -1.7)	2004-2023
																						-0.6 (-1.3; 0.2)	2004-2010
																						-3.1 (-4.0; -2.2)	2011-2014
																						-2.2 (-2.7; -1.8)	2015-2023
Brussels	**N**	227	196	200	211	212	233	194	253	191	204	206	186	193	178	192	175	161	168	168	176		
	CR	43.7	37.5	37.8	39.5	39.1	42.2	34.5	43.9	32.6	34.4	34.5	30.9	31.7	29.2	31.4	28.4	25.9	27.1	27.0	27.8		
	ESR2013	45.7	39.5	40.7	41.9	42.7	46.1	38.0	49.3	38.7	39.9	39.6	35.8	36.7	33.7	35.8	32.9	29.5	30.8	30.6	31.3	-1.9 (-2.5; -1.4)	2004-2023
																						0.1 (-1.6; 1.8)	2004-2011
																						-3.1 (-4.0; -2.2)	2012-2023
Flanders	**N**	1,355	1,322	1,344	1,405	1,356	1,374	1,467	1,351	1,366	1,317	1,329	1,251	1,288	1,269	1,314	1,238	1,223	1,186	1,239	1,242		
	CR	44.4	43.2	43.6	45.3	43.4	43.7	46.3	42.3	42.5	40.8	41.0	38.4	39.3	38.5	39.7	37.2	36.5	35.3	36.6	36.3		
	ESR2013	45.1	43.8	43.4	44.5	42.1	42.1	44.0	40.1	39.4	38.1	37.3	34.4	35.0	33.8	34.4	31.6	31.1	29.7	30.6	30.0	-2.2 (-2.5; -1.9)	2004-2023
																						-0.6 (-2.3; 1.0)	2004-2008

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
																						-2.6 (-3.9; -1.3)	2009-2012
																						-2.7 (-3.1; -2.2)	2013-2023
Wallonia	**N**	694	736	704	732	779	741	691	784	755	767	702	730	745	748	716	662	674	694	700	691		
	CR	39.9	42.1	40.1	41.4	43.8	41.5	38.4	43.3	41.5	41.9	38.3	39.7	40.4	40.4	38.6	35.6	36.2	37.2	37.4	36.7		
	ESR2013	41.0	42.5	40.2	40.9	43.2	41.0	37.6	41.9	39.2	40.0	36.5	36.7	37.6	36.9	35.4	31.9	32.7	33.6	33.4	32.6	-1.5 (-1.8; -1.1)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.2. Female breast cancer mortality trends: by age group

7.2.1. Female breast cancer mortality trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024*

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, %	(95%CI)	Period
15-49	**N**	251	210	202	222	219	195	183	202	182	160	180	141	157	153	144	122	139	129	136	130			
	CR	10.2	8.5	8.1	8.9	8.8	7.8	7.3	8.0	7.2	6.4	7.2	5.6	6.3	6.1	5.8	4.9	5.6	5.2	5.4	5.1			
	ESR2013	10.1	8.4	8.0	8.8	8.7	7.7	7.3	8.0	7.2	6.4	7.2	5.7	6.4	6.3	5.9	5.0	5.8	5.3	5.7	5.4	-3.1	(-3.6; -2.5)	2004-2023
50-69	**N**	806	855	798	801	814	822	817	808	767	812	745	729	691	704	712	624	593	580	566	570			
	CR	68.4	71.7	65.9	65.1	65.1	64.7	63.2	61.2	56.6	58.8	53.1	51.1	47.8	48.4	48.7	42.5	40.1	39.0	37.9	37.9			
	ESR2013	69.2	72.5	66.8	66.1	66.1	65.9	64.2	62.1	57.8	59.3	53.5	51.3	47.9	48.5	48.8	42.4	39.9	38.8	37.5	37.4	-3.5	(-3.7; -3.2)	2004-2023
																						-1.8	(-2.6; -1.0)	2004-2011
																						-4.4	(-4.9; -4.0)	2012-2023
70+	**N**	1,219	1,189	1,248	1,325	1,314	1,331	1,352	1,378	1,363	1,316	1,312	1,297	1,378	1,338	1,366	1,329	1,326	1,339	1,405	1,409			
	CR	155.7	150.1	156.1	164.1	161.2	161.4	162.3	164.8	163.4	158.0	156.7	153.4	161.9	154.3	155.0	148.4	145.8	146.3	151.2	149.5			
	ESR2013	156.9	150.9	155.7	162.4	157.8	157.9	157.7	159.8	154.0	150.8	147.1	141.5	150.4	141.5	143.0	135.4	135.3	134.6	139.8	137.1	-0.7	(-0.9; -0.5)	2004-2023
																						0.6	(-0.2; 1.5)	2004-2010
																						-2.2	(-3.2; -1.1)	2011-2014
																						-0.9	(-1.4; -0.4)	2015-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

8. CANCER INCIDENCE (MALES)

8.1. Male breast cancer incidence: by region

8.1.1. Male breast cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Males																						
Belgium	0	0	0	0	0	0	0	1	3	3	4	4	11	20	21	16	6	4	4	2	99	1.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.8]	[0.8]	[1.0]	[1.0]	[2.9]	[6.2]	[7.8]	[7.5]	[4.7]	[4.9]	[12.3]	[31.4]	[1.7]	(1.5; 2.2)
Brussels	0	0	0	0	0	0	0	0	1	0	2	0	0	1	0	1	1	0	0	0	6	1.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.2]	[0.0]	[4.8]	[0.0]	[0.0]	[4.6]	[0.0]	[7.8]	[12.2]	[0.0]	[0.0]	[0.0]	[1.0]	(0.2; 2.5)
Flanders	0	0	0	0	0	0	0	1	1	2	1	3	8	11	12	12	5	3	2	1	62	1.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.4]	[0.9]	[0.4]	[1.3]	[3.4]	[5.5]	[7.2]	[8.9]	[6.0]	[5.4]	[9.1]	[23.8]	[1.8]	(1.4; 2.3)
Wallonia	0	0	0	0	0	0	0	0	1	1	1	1	3	8	9	3	0	1	2	1	31	1.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.9]	[0.8]	[0.8]	[2.5]	[7.8]	[10.5]	[4.6]	[0.0]	[4.7]	[23.6]	[62.3]	[1.7]	(1.2; 2.6)

Belgian Cancer Registry

9. CANCER INCIDENCE TRENDS (MALES)

9.1. Male breast cancer incidence trends: by region

9.1.1. Male breast cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	**N**	87	83	65	82	86	98	84	76	80	80	91	92	111	104	103	94	99	114	109	104	99		
	CR	1.7	1.6	1.3	1.6	1.6	1.9	1.6	1.4	1.5	1.5	1.7	1.7	2.0	1.9	1.8	1.7	1.7	2.0	1.9	1.8	1.7		
	ESR2013	2.1	2.2	1.7	2.0	2.0	2.2	1.8	1.7	1.8	1.8	1.9	2.0	2.3	2.1	2.1	1.8	1.9	2.2	2.1	1.9	1.8	0.0 (-0.7; 0.8)	2004-2024
Brussels	**N**	7	7	8	8	6	7	9	6	10	5	11	3	8	3	6	8	8	8	4	7	6		
	CR	1.5	1.4	1.6	1.6	1.2	1.4	1.7	1.1	1.8	0.9	1.9	0.5	1.4	0.5	1.0	1.4	1.3	1.3	0.7	1.2	1.0		
	ESR2013	1.8	2.6	2.4	2.8	1.7	1.6	2.4	1.8	2.9	1.5	3.0	0.8	2.1	0.8	1.6	2.0	1.7	2.0	1.0	1.7	1.4	-2.5 (-5.0; 0.0)	2004-2024
Flanders	**N**	56	50	37	54	51	53	48	49	42	48	57	59	74	71	65	61	71	62	67	65	62		
	CR	1.9	1.7	1.2	1.8	1.7	1.7	1.6	1.6	1.3	1.5	1.8	1.9	2.3	2.2	2.0	1.9	2.2	1.9	2.0	1.9	1.8		
	ESR2013	2.2	2.1	1.6	2.1	1.9	1.9	1.6	1.8	1.5	1.7	1.9	2.1	2.5	2.3	2.1	1.9	2.2	1.9	2.1	1.9	1.8	0.3 (-0.7; 1.2)	2004-2024
Wallonia	**N**	24	26	20	20	29	38	27	21	28	27	23	30	29	30	32	25	20	44	38	32	31		
	CR	1.5	1.6	1.2	1.2	1.7	2.3	1.6	1.2	1.6	1.6	1.3	1.7	1.7	1.7	1.8	1.4	1.1	2.5	2.1	1.8	1.7		
	ESR2013	2.1	2.0	1.8	1.6	2.2	2.9	2.1	1.4	2.1	1.9	1.5	2.3	1.9	2.0	2.3	1.6	1.2	2.8	2.4	1.8	1.9	0.0 (-1.7; 1.6)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

Belgian Cancer Registry

10. CANCER PREVALENCE (MALES)

10.1. Male breast cancer prevalence: by region

10.1.1. Male breast cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024

Region		Males				
		1-year	5-year	10-year	15-year	20-year
Belgium	**N**	88	433	724	896	997
	CR	1.5	7.4	12.4	15	17
	ESR2013	1.6	7.7	13.0	16.2	18.0
Brussels	**N**	5	30	45	61	71
	CR	0.8	4.9	7.3	9.9	11.5
	ESR2013	1.1	7.1	10.8	15.2	17.9
Flanders	**N**	56	275	471	583	644
	CR	1.6	8.1	13.9	17.1	18.9
	ESR2013	1.6	7.8	13.5	16.7	18.4
Wallonia	**N**	27	128	208	252	282
	CR	1.5	7.1	11.5	13.9	15.5
	ESR2013	1.7	7.5	12.4	15.1	16.9

11. CANCER SURVIVAL (MALES)

11.1. Male breast cancer survival: by region

11.1.1. Male breast cancer survival by region and age group: number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024			
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Males						
Belgium	**All ages 15+**	1,024	96.3% (94.6%; 98.1%)	91.0% (87.8%; 94.3%)	87.3% (82.8%; 92.1%)	65.2% (44.1%; 96.2%)
	15-49	59	96.7% (92.2%; 101.4%)	95.4% (89.8%; 101.4%)	93.5% (86.4%; 101.2%)	69.6% (50.2%; 96.4%)
	50-69	417	97.2% (95.4%; 99.1%)	94.4% (91.5%; 97.4%)	90.2% (86.2%; 94.4%)	88.5% (81.5%; 96.0%)
	70+	548	95.6% (92.8%; 98.5%)	87.9% (82.6%; 93.6%)	84.5% (76.9%; 92.9%)	50.4% (25.2%; 100.8%)
Brussels	**All ages 15+**	60	97.2% (91.6%; 103.0%)	99.1% (90.5%; 108.5%)	93.2% (78.9%; 110.1%)	FU<10y
	15-49	7	N<50	N<50	N<50	N<50
	50-69	31	N<50	N<50	N<50	N<50
	70+	22	N<50	N<50	N<50	N<50
Flanders	**All ages 15+**	654	98.3% (96.4%; 100.2%)	93.3% (89.5%; 97.1%)	91.8% (86.4%; 97.6%)	68.2% (41.6%; 111.9%)
	15-49	30	N<50	N<50	N<50	N<50
	50-69	252	99.8% (98.4%; 101.1%)	96.8% (93.7%; 100.0%)	94.6% (90.4%; 99.1%)	93.4% (85.8%; 101.7%)
	70+	372	97.4% (94.2%; 100.6%)	90.8% (84.8%; 97.2%)	89.9% (81.1%; 99.8%)	54.7% (24.7%; 121.0%)
Wallonia	**All ages 15+**	310	91.8% (88.0%; 95.7%)	84.6% (78.2%; 91.6%)	76.2% (67.6%; 85.9%)	56.2% (37.9%; 83.3%)
	15-49	22	N<50	N<50	N<50	N<50

Net Survival Probability, 2015-2024						
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	50-69	134	91.9% (87.1%; 96.9%)	88.5% (82.2%; 95.4%)	80.9% (72.4%; 90.3%)	77.4% (63.2%; 94.9%)
	70+	154	90.7% (84.6%; 97.3%)	79.6% (68.7%; 92.3%)	69.3% (55.1%; 87.2%)	37.8% (16.1%; 88.5%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

Belgian Cancer Registry

12. CANCER SURVIVAL TRENDS (MALES)

12.1. Male breast cancer survival trends

12.1.1. Male breast cancer survival trends: number at risk and net survival probabilities, 2004-2024

Period	Net Survival Probability			
	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2009	**498**	93.9% (91.1%; 96.7%)	86.8% (82.4%; 91.3%)	79.6% (74.0%; 85.5%)
2010-2014	**409**	95.3% (92.7%; 98.1%)	90.9% (86.3%; 95.8%)	81.0% (74.6%; 87.9%)
2015-2019	**502**	96.9% (94.4%; 99.4%)	91.4% (86.9%; 96.2%)	89.5% (83.5%; 96.0%)
2020-2024	**522**	95.8% (93.4%; 98.3%)	90.5% (86.2%; 95.1%)	83.0% (76.0%; 90.6%)

Belgian Cancer Registry

13. CANCER MORTALITY (MALES)

13.1. Male breast cancer mortality

13.1.1. Male breast cancer mortality: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023*

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Belgium	0	0	0	0	0	0	0	0	0	0	1	1	3	3	2	3	4	5	3	0	25	0.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.2]	[0.8]	[0.9]	[0.8]	[1.5]	[3.2]	[6.3]	[9.6]	[0.0]	[0.4]	(0.3; 0.7)

Belgian Cancer Registry

14. CANCER MORTALITY TRENDS (MALES)

14.1. Male breast cancer mortality trends

14.1.1. Male breast cancer mortality trends: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	19	18	16	17	26	21	20	30	22	19	21	17	19	20	21	25	26	21	17	25		
	CR	0.4	0.4	0.3	0.3	0.5	0.4	0.4	0.6	0.4	0.3	0.4	0.3	0.3	0.4	0.4	0.4	0.5	0.4	0.3	0.4		
	ESR2013	0.5	0.5	0.4	0.5	0.8	0.5	0.5	0.7	0.5	0.5	0.5	0.4	0.4	0.5	0.4	0.5	0.5	0.4	0.3	0.5	-1.3 (-2.6; 0.0)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2023.

Recommended reference: Cancer Fact Sheets 2024, Belgian Cancer Registry (BCR), 2026